WO2004044155A8 - MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE - Google Patents

MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Info

Publication number
WO2004044155A8
WO2004044155A8 PCT/US2003/035693 US0335693W WO2004044155A8 WO 2004044155 A8 WO2004044155 A8 WO 2004044155A8 US 0335693 W US0335693 W US 0335693W WO 2004044155 A8 WO2004044155 A8 WO 2004044155A8
Authority
WO
WIPO (PCT)
Prior art keywords
mip
csf
adjuvants
vaccine
immune response
Prior art date
Application number
PCT/US2003/035693
Other languages
French (fr)
Other versions
WO2004044155A3 (en
WO2004044155A2 (en
Inventor
Paul Mckay
Dan Barouch
Norman Letvin
Original Assignee
Beth Israel Hospital
Paul Mckay
Dan Barouch
Norman Letvin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Paul Mckay, Dan Barouch, Norman Letvin filed Critical Beth Israel Hospital
Priority to AU2003291402A priority Critical patent/AU2003291402A1/en
Publication of WO2004044155A2 publication Critical patent/WO2004044155A2/en
Publication of WO2004044155A8 publication Critical patent/WO2004044155A8/en
Publication of WO2004044155A3 publication Critical patent/WO2004044155A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention features methods to substantially increase the immunogenicity of a vaccine, preferably a DNA vaccine, and involves providing a mammal with a vaccine regimen, which include at least one immunogen, GM-CSF, and MIP- I α in the absence of exogenous IL-4. The methods of the present invention are useful for the prevention, treatment, and reduction of various pathological states, including for example, cancer, microbial infections, autoimmune diseases, tissue rejection, and allergic reactions.
PCT/US2003/035693 2002-11-07 2003-11-07 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE WO2004044155A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291402A AU2003291402A1 (en) 2002-11-07 2003-11-07 MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42465802P 2002-11-07 2002-11-07
US60/424,658 2002-11-07

Publications (3)

Publication Number Publication Date
WO2004044155A2 WO2004044155A2 (en) 2004-05-27
WO2004044155A8 true WO2004044155A8 (en) 2004-08-19
WO2004044155A3 WO2004044155A3 (en) 2005-10-06

Family

ID=32312848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035693 WO2004044155A2 (en) 2002-11-07 2003-11-07 MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Country Status (2)

Country Link
AU (1) AU2003291402A1 (en)
WO (1) WO2004044155A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662781B2 (en) * 2005-01-31 2010-02-16 Eci, Inc. Immunopotentiating agent
WO2009024426A1 (en) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunizing compositions for inducing 'bystander' killing of pathogens
PT2340038T (en) 2008-10-10 2018-02-21 Beth Israel Deaconess Medical Ct Inc Biochemically stabilized hiv-1 env trimer vaccine
WO2012023631A1 (en) * 2010-08-19 2012-02-23 株式会社Eci Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same
CA2897059C (en) 2013-01-07 2021-12-28 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
DK3052518T3 (en) 2013-10-04 2020-04-06 Beth Israel Deaconess Medical Ct Inc STABILIZED HUMAN IMMUNE DEFECT VIRUS (HIV) -CLADE C-CAPE (ENV) TRIMER VACCINES AND METHODS OF USING IT
RS61902B1 (en) 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
MA44059B1 (en) 2015-12-15 2019-11-29 Janssen Vaccines & Prevention Bv Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3471765B1 (en) 2016-06-16 2024-04-24 Janssen Vaccines & Prevention B.V. Hiv vaccine formulation
US10307477B2 (en) 2016-09-02 2019-06-04 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
MX2019002938A (en) 2016-09-15 2019-10-15 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations.
EP3526236A4 (en) 2016-10-17 2020-06-03 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
AU2018283811B2 (en) 2017-06-15 2022-10-20 Bavarian Nordic A/S Poxvirus vectors encoding HIV antigens, and methods of use thereof
SG11202000112XA (en) 2017-07-19 2020-02-27 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
EP3797118A4 (en) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
WO2022182940A1 (en) * 2021-02-26 2022-09-01 The Feinstein Institutes For Medical Research Neural control of adaptive immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation

Also Published As

Publication number Publication date
AU2003291402A8 (en) 2004-06-03
AU2003291402A1 (en) 2004-06-03
WO2004044155A3 (en) 2005-10-06
WO2004044155A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO2005052119A3 (en) Adjuvants of immune response
WO2004044155A3 (en) MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
WO2004084936A3 (en) Modified free-living microbes, vaccine compositions and methods of use thereof
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
WO2009135199A3 (en) Vaccine compositions and methods
WO2008052770A3 (en) (base-)modified rna for increasing the expression of a protein
NO20015073L (en) vaccinations
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
EP2433954A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
BR0316758A (en) Yeast-based vaccines as immunotherapy
WO2007006712A3 (en) Mycoplasma subunit vaccine
AU2002338832A1 (en) Vaccine
WO2006113622A3 (en) Direct vaccination of the bone marrow
WO2006029029A3 (en) Compositions for detection of latent hiv reactivation and methods of using the same
WO2003090687A3 (en) Using heat shock proteins to increase immune response
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
EP2420509A3 (en) Novel marker genes for regulatory T cells from human blood
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2004084935A3 (en) Francisella strain for live vaccine
MY127452A (en) Vaccines.
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 22/2004 UNDER (72, 75) REPLACE "MCKAY, PAUL [GB/GB]; LONDON (GB)." BY "MCKAY, PAUL [GB/GB]; 10 STRILING GROVE, HOUNSLOW, MIDDLESEX, LONDON TW3 1QG (GB)."; "BAROUCH, DAN [US/US]; BROOKLINE, MA (US)." BY "BAROUCH, DAN [US/US] 1 LONGFELLOW PLACE, #3222, BOSTON, MA 02114 (US)."; LETVIN, NORMAN [US/US]; NEWTON, MA (US)." REPLACE "LETVIN, NORMAN [US/US]; 36 BRACKET ROAD, NEWTON, MA 02458 (US)."

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP